Jieduquyuziyin Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1α pathway in glucocorticoid-induced MRL/lpr mice.
Animals
Drugs, Chinese Herbal
/ therapeutic use
Female
Glucocorticoids
Gluconeogenesis
/ drug effects
Humans
Liver
/ drug effects
Mice
Mice, Inbred Strains
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
/ genetics
Phosphatidylinositol 3-Kinases
/ genetics
Phytotherapy
Proto-Oncogene Proteins c-akt
/ genetics
Hepatic gluconeogenesis
Hepatocytes
Jieduquyuziyin prescription
MRL/lpr mice
PI3K/Akt/PGC-1α
Systemic lupus erythematosus
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
10 Feb 2022
10 Feb 2022
Historique:
received:
23
07
2021
revised:
25
10
2021
accepted:
04
11
2021
pubmed:
12
11
2021
medline:
26
2
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Jieduquyuziyin prescription (JP) is a traditional Chinese medicine (TCM) formula. According to both TCM theory and more than a decade of clinical practice, JP has been testified to be effective for systemic lupus erythematosus (SLE) treatment as an approved hospital prescription in China. To determine the effect of JP on the treatment of SLE by glucocorticoid (GC) and to further examine the molecular mechanisms. We conducted in vivo experiments to estimate the effect of JP on hepatic gluconeogenesis in MRL/lpr mice treated with GC. Additionally, isoproterenol (ISO) induced hepatic gluconeogenesis model and GC-treated MRL/lpr mouse hepatocytes were carried out in vitro experiments to verify the effect of JP on gluconeogenesis. The results showed that JP combined with GC could effectively alleviate the lupus symptoms in MRL/lpr mice and improve the pathological changes of the kidney and liver. And the combination of JP reduced the side effects caused by GC, which was related to the inhibition of GC-induced hepatic gluconeogenesis in MRL/lpr mice. Specifically, JP up-regulated the expression of glucocorticoid receptor (GR) α, phosphoinositide-3-kinase (PI3K) and Akt restrained by GC to reduce the production of forkhead box O1 (FoxO1), peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), and the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). In vivo, the use of JP either alone or with GC could reduce spleen enlargement, high levels of serum antibodies, aggravated urine protein and renal pathological damage in MRL/lpr mice. Furthermore, the glucose content was reduced in the liver of MRL/lpr mice treated with JP, and the liver damage and steatosis were also alleviated. In vitro, the expressions of PI3K and Akt increased and the expressions of FoxO1, PGC-1α, PEPCK and G6Pase decreased after JP treatment in ISO-treated hepatocytes. Compared with MRL/MP mice, we found that JP could significantly inhibit the expression of gluconeogenesis in the hepatocytes of MRL/lpr mice induced by GC to a greater extent. The therapeutic effect of JP on GC-induced is likely related to hepatic gluconeogenesis, which provides a new perspective to reveal the positive role of JP in SLE.
Identifiants
pubmed: 34763039
pii: S0378-8741(21)01045-X
doi: 10.1016/j.jep.2021.114815
pii:
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Glucocorticoids
0
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
0
Ppargc1a protein, mouse
0
jieduquyuziyin
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114815Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.